Stevens Capital Management’s Quest Diagnostics DGX Stock Holding History

Stevens Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,095	Closed	-$364K	–	243
2025 Q4	$364K	Buy	+2,095	New	+$381K	0.13%	147
2025 Q1	–	Sell	-2,361	Closed	-$356K	–	280
2024 Q4	$356K	Buy	+2,361	New	+$367K	0.14%	195
2023 Q4	–	Sell	-1,810	Closed	-$221K	–	266
2023 Q3	$221K	Buy	+1,810	New	+$241K	0.06%	212
2021 Q1	–	Sell	-1,801	Closed	-$215K	–	145
2020 Q4	$215K	Buy	+1,801	New	+$220K	0.11%	141
2019 Q1	–	Sell	-9,212	Closed	-$767K	–	724
2018 Q4	$767K	Sell	9,212 -78,753	-90%	-$7.38M	0.04%	431
2018 Q3	$9.49M	Buy	+87,965	New	+$9.65M	0.35%	85
2017 Q3	–	Sell	-2,208	Closed	-$245K	–	895
2017 Q2	$245K	Buy	+2,208	New	+$233K	0.01%	727
2014 Q3	–	Sell	-11,105	Closed	-$652K	–	1048
2014 Q2	$652K	Buy	+11,105	New	+$650K	0.02%	591
2014 Q1	–	Sell	-187,508	Closed	-$10M	–	1107
2013 Q4	$10M	Buy	+187,508	New	+$11.1M	0.3%	87

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Stevens Capital Management's DGX Position: Q1 2026 in Review

Stevens Capital Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 2,095 shares — an estimated $364K sold.

Stevens Capital Management first reported a position in DGX in Q4 2013 and held it in 9 quarters. The position peaked at $10M in Q4 2013. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Stevens Capital Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
Stevens Capital Management sold 2,095 Quest Diagnostics shares in Q1 2026, an estimated $364K.
Stevens Capital Management first reported a position in Quest Diagnostics in Q4 2013 and held it in 9 quarters.
Stevens Capital Management's Quest Diagnostics position peaked at $10M in Q4 2013.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Stevens Capital Management's 13F filing for Q1 2026, filed 11 May 2026.